RxDoctor Payments Data

Krystal Kennedy

Nurse Practitioner · Greenville, NCNPI 1598363681

Payments from drug & device makers

$8,115in general payments, 2019–2025

Across 516 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novartis$619
  • AbbVie$612
  • Novo Nordisk$602
  • Lilly USA, LLC$421
  • Regeneron Healthcare Solutions, Inc.$420
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$8,115100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,115 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$34,931
Medicare patients
142
Services billed
1,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$29,369
JardianceEmpagliflozin14$13,178
Repatha SureclickEvolocumab19$12,015
Epinephrine32$5,929
Arnuity ElliptaFluticasone Furoate22$5,849
Fluticasone Propionate HfaFluticasone Propionate17$3,639
SymbicortBudesonide/Formoterol Fumarate15$3,393
Fluticasone Propionate112$1,992
Potassium Chloride23$1,285
SynthroidLevothyroxine Sodium11$1,142
Albuterol Sulfate HfaAlbuterol Sulfate46$1,139
Ventolin HfaAlbuterol Sulfate15$1,081
Montelukast Sodium66$1,050
Famotidine58$926
Omeprazole48$847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta$413$35,21857 claims
Boehringer IngelheimJardiance$137$13,17814 claims
Hikma Pharmaceuticals USAEpinephrine$58$5,92932 claims
AstraZenecaSymbicort$1,091$3,39315 claims
AbbVieSynthroid$612$1,14211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →